Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Line of DNA Amplification Reagents Promises Consistent Results Across All PCR Instruments

By BiotechDaily International staff writers
Posted on 02 Sep 2013
Image: iTaq Universal SYBR Green Supermix (Photo courtesy of Bio-Rad).
Image: iTaq Universal SYBR Green Supermix (Photo courtesy of Bio-Rad).
New reagent mixes specially formulated for PCR applications are now available for biotech and genomics researchers.

Bio-Rad Laboratories, Inc. (Hercules, CA, USA) recently launched two iTaq universal one-step kits aimed to deliver superior data precision and highly efficient reverse transcription quantitative PCR (RT-qPCR) performance under most reaction conditions on any qPCR instrument.

The new iTaq universal one-step kit line includes the iTaq universal SYBR Green one-step kit and the iTaq universal probes one-step kit. Both kits come as a double concentrated, ready-to-use reaction mixes with iScript reverse transcriptase optimized for RT-qPCR.

The iTaq universal SYBR Green one-step kit includes SYBR Green I dye and Bio-Rad’s patented RT inhibitor reducer. The iTaq universal probes one-step kit allows researchers to combine multiple targets in one well (multiplexing), improving data precision and reducing costs.

The new kits enable investigators to obtain reliable and reproducible gene expression-analysis results while amplifying genomic DNA and difficult amplicons with superior efficiency. Results are consistent across real-time instrument platforms under fast or standard conditions.

The Bio-Rad Kits are intended for gene expression analysis, genotyping, mutation detection, and pathogen detection.

Related Links:
Bio-Rad Laboratories, Inc.




Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Therapeutics

view channel
Image: A photmicrograph of medium spiny neurons (yellow) with nuclear inclusions (orange), which occur as part of the Huntington\'s disease process. Several neurons are colored yellow and have a large central core with up to two dozen tendrils branching out of them. The core of the neuron in the foreground contains an orange blob about a quarter of its diameter (Photo courtesy of Wikimedia Commons).

Seeding Assay May Boost Search for Huntington's Disease Drugs

An assay technique that measures seeding of mutant huntingtin aggregates in cerebral spinal fluid (CSF) may identify individuals with Huntington's disease (HD) that have not yet become symptomatic and... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.